1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.


The RNA-dependent RNA polymerase (NS5B) of hepatitis C virus (HCV) is an unusually attractive target for drug discovery since it contains five distinct drugable sites. The success of novel antiviral therapies will require nonnucleoside inhibitors to be active in at least patients infected with HCV of subtypes 1a and 1b. Therefore, the genotypic assessment… (More)
DOI: 10.1128/JVI.01980-09